The global genome editing market was valued at USD 9.9 billion in 2025 and is projected to grow from USD 11.57 billion in 2026 to USD 40.36 billion by 2034, registering a CAGR of 16.9% during 2026–2034. Growth is being supported by expanding applications of CRISPR-based technologies across therapeutic development, agricultural biotechnology, disease modeling, cell engineering, and precision medicine. North America dominated the market with a 42.5% share in 2025, while Asia Pacific is expected to record the fastest growth during the forecast period.
Market Size (2025): USD 9.9 Billion
Market Size (2026): USD 11.57 Billion
CAGR (Forecast Period): 16.9%
Forecast Year: 2034
Projected Market Size (2034): USD 40.36 Billion
Dominant Region: North America – 42.5% share in 2025
Fastest Growing Region: Asia Pacific – 19.4% CAGR during 2026–2034
Genome editing includes technologies that enable targeted addition, removal, or modification of genetic material at specific locations within an organism’s DNA. CRISPR-Cas9 has become one of the most widely adopted genome-editing approaches because of its programmable targeting, efficiency, accuracy, and relatively straightforward design compared with earlier technologies.
The market is evolving rapidly as genome editing moves from laboratory research toward therapeutic development, agricultural improvement, disease modeling, and advanced biomanufacturing. Continued progress in delivery systems and compact editing technologies is further expanding the range of tissues and applications that can be targeted.
Agricultural biotechnology is supporting wider use of genome-editing technologies for introducing targeted characteristics into crops and livestock. Applications include disease resistance, environmental tolerance, productivity improvement, and faster development of desirable traits.
Therapeutic programs for genetic diseases represent another major growth driver. Genome editing allows researchers to address disease-causing mutations at their biological source, supporting investment in editing platforms, delivery technologies, personalized therapies, clinical research, and precision medicine programs.
Patient-specific manufacturing remains a major challenge for companies developing ex vivo genome-edited therapies. Cell collection, editing, quality testing, preservation, transportation, and individualized processing increase operational complexity and make large-scale commercialization more difficult.
Small patient populations for rare genetic diseases also complicate clinical development. Limited eligible populations can restrict traditional trial designs, extend evidence-generation timelines, and make commercialization decisions more challenging for highly targeted therapies.
Genome editing services are creating new opportunities for specialized research providers, biotechnology developers, pharmaceutical companies, and contract research organizations. Revenue potential is expanding across custom cell-line engineering, assay development, screening, validation, and outsourced research programs.
Disease modeling and organoid development represent another promising opportunity. Genome-edited cellular and organoid models can support target validation, toxicity testing, drug screening, and preclinical research, opening additional commercial avenues for technology providers and research service companies.
By technology, CRISPR dominated the genome editing market with a 68.4% share in 2025 and is also expected to register the fastest CAGR of 18.7% during 2026–2034. TALEN and ZFN technologies remain relevant for specialized editing programs requiring customized DNA recognition and validated platforms.
By application, cell line engineering held a 39.2% share in 2025, while plant genetic engineering is projected to grow at a CAGR of 18.3%. By end-user, pharmaceutical and biotechnology companies dominated with a 48.6% share, while contract research organizations are expected to register the fastest 18.8% CAGR.
North America accounted for the largest 42.5% share in 2025, supported by strong biomedical research infrastructure, advanced therapeutic development, and broad adoption of genome-editing tools across drug discovery and functional genomics.
Asia Pacific is expected to be the fastest-growing region with a 19.4% CAGR during 2026–2034. Regional growth is supported by expanding biotechnology research, bioeconomy programs, agricultural applications, biomanufacturing initiatives, and stronger investment in advanced life-science technologies.
Europe is projected to register a 15.6% CAGR, supported by genomic research programs, precision medicine initiatives, growing genetic datasets, and investment in biotechnology innovation.
The genome editing market includes biotechnology companies, life-science tool providers, contract development organizations, and gene-therapy specialists competing through intellectual property, editing capabilities, clinical expertise, research partnerships, and specialized service models.
Key market players include:
Merck KGaA
GenScript
Sangamo Therapeutics
Lonza
Editas Medicine
CRISPR Therapeutics
Precision BioSciences
Cellectis S.A.
Thermo Fisher Scientific Inc.
QIAGEN N.V.
Agilent Technologies, Inc.
Bio-Rad Laboratories, Inc.
During 2025, genome-editing companies continued expanding CRISPR-based therapeutic programs across inherited diseases, oncology, regenerative medicine, rare genetic disorders, and engineered immune-cell therapies. Development activity increasingly focused on advancing clinical pipelines, strengthening in vivo editing capabilities, and improving precision across therapeutic applications.
Click Here to Access the Comprehensive Report:https://straitsresearch.com/report/genome-editing-market
The genome editing market is expected to maintain strong growth through 2034 as CRISPR technologies become more integrated into therapeutic research, agricultural biotechnology, cell engineering, and precision medicine. Advances in compact gene editors, non-viral delivery, tissue-specific targeting, organoid development, and outsourced editing services are expected to broaden commercial applications. Continued improvement in safety assessment, delivery efficiency, manufacturing scalability, and clinical validation will remain central to long-term market expansion.
Straits Research is a global market intelligence and consulting company providing in-depth market research, competitive analysis, strategic consulting, and industry insights across major global sectors. The company supports organizations in evaluating market trends, emerging technologies, competitive dynamics, regional opportunities, and long-term growth strategies for informed business decision-making.